This study investigates the poor reversibility of salmon calcitonin (sCT) binding to rat and human calcitonin receptors. Efficacy of CT and analogue peptides in 125 I-sCT binding competition and cAMP assays was compared with the dissociation kinetics of 125 I-labelled peptides. Assessment was performed on cells stably expressing either rat or human calcitonin receptors. Dissociation kinetics of the antagonists, sCT(8-32) and AC512, revealed that binding was rapidly and completely reversible at the receptors, despite high affinity binding, suggesting that poor reversibility required the active conformation of the receptor. G protein coupling was not essential as the dissociation kinetics of 125 I-sCT binding to cell membranes did not significantly alter in the presence of GTP S. Time course experiments established that the transition to irreversibility was slow, while the reversible component of binding appeared to involve a single population of either receptor states or binding sites. Pre-bound 125 I-human CT dissociated rapidly from the receptors, indicating that not all agonists bound irreversibly. To identify structural features of sCT that contribute to its poor reversibility, dissociation kinetics of sCT analogues with various structural modifications were examined. Increasing truncation of N-terminal residues of sCT analogues led to a corresponding increase in the rate of peptide dissociation. Salmon CT peptides which had been substituted at the N-terminus by 13-21 residues of human CT (hCT) were equipotent with sCT in binding competition and cAMP accumulation assays but exhibited a dissociation rate similar to hCT. In contrast, despite lower affinity and efficacy at the receptors, the chimeric analogue sCT(1-16)-hCT(17-32) displayed poorly reversible binding, similar to sCT. Analysis of the dissociation kinetics of sCT analogues with differing -helix forming potential indicated that the ability to form -helical secondary structure was an important factor in the rate of ligand dissociation. We hypothesise that poor reversibility results from a conformational change in the receptor and/or ligand and that this is dependent, at least in part, on interaction with residues constrained within the -helix of the peptide. Human embryonic kidney (HEK)-293-and baby hamster kidney (BHK)-derived cell lines were maintained in J M HILTON and others · Calcitonin ligand-receptor dissociation 214 www.endocrinology.org Journal of Endocrinology (2000) 166, 213-226 a Epand et al. (1988); b Nakamuta et al. (1990); c Epand et al. (1985). Aib, amino isobutyric acid; For, formyl; Ip, isopropyl; Ac, N-terminal acetylation. *Structures lack disulphide bridged cysteines at residues 1 and 7.
Introduction
The calcitonins (CTs) are 32 amino acid peptide hormones whose best recognised action is inhibition of bone resorption (Azria et al. 1995) . This occurs through an action at specific receptors on osteoclasts to inhibit activity (Nicholson et al. 1986 ). CT receptors also occur in kidney and brain. In kidney, CT modulates calcium and magnesium excretion, while in the brain central actions include analgesia, appetite suppression and modulation of hormone release (Sexton et al. 1987 , Sexton 1991 .
Calcitonin receptors (CTRs) have been cloned from a number of species including rat (Sexton et al. 1993 ) and human (Gorn et al. 1992 , Kuestner et al. 1994 . The CTRs belong to the family B (class II) subfamily of the 7 transmembrane domain G protein-coupled superfamily of receptors. This family includes the receptors for parathyroid hormone/parathyroid hormone related protein (PTH/PTHrP), growth hormone-releasing hormone, secretin, pituitary adenylate cyclase-activating peptide (PACAP), vasoactive intestinal peptide, glucagon and glucagon-like peptide (Peroutka 1994) . These receptors share 30 to 50% amino acid sequence identity with each other but have little identity with other G protein-coupled receptors.
CTRs occur as distinct isoforms resulting from alternate splicing of the primary RNA transcripts. In rat, the principle receptor isoforms, C1a and C1b, differ by the absence or presence, respectively, of a 37 amino acid insert in the predicted second extracellular domain (Sexton et al. 1993) . The rat C1b receptor exhibits altered binding kinetics and ligand recognition compared with the C1a isoform (Houssami et al. 1994a) . In humans, although additional splice variation may occur in 5 regions of the coding sequence (Albrandt et al. 1995 , Gorn et al. 1995 , the most common splice variation generates isoforms that differ by the presence (hCTR I1+ ) or absence (hCTR I1 ) of a 16 amino acid insert into the first intracellular domain (I1) of the receptor (Gorn et al. 1992 , Kuestner et al. 1994 . Analysis of the function of the I1 insert demonstrates that while ligand recognition remains essentially unchanged, G protein-mediated signalling is markedly impaired . This is particularly true for release of intracellular calcium, presumably mediated by coupling to Gq (Offermanns et al. 1996) , as no signal was seen in insert-positive receptor . However, EC 50 values for ligand-stimulated cAMP response were also shifted approximately 2 orders of magnitude to the right, indicating an impairment of Gs coupling also . The hCTR I1+ isoform also exhibited loss of ligand-induced internalisation .
Biochemical characterization of ligand-receptor interactions for CT have predominantly employed 125 I-labelled salmon CT ( 125 I-sCT) (a member of the teleost class of CT), as this class of CT has the highest intrinsic activity, is less prone to degradation and lacks Met residues in its sequence, which in other CTs may become oxidised during iodination resulting in loss of biological activity. In virtually all the systems studied, the binding of 125 I-sCT to its receptor has been essentially irreversible. This is true of human or rat tissue membrane preparations (Fischer et al. 1981 , Nicholson et al. 1988b , as well as clonal cell lines of rat or human origin (Findlay et al. 1981 , Chao & Forte 1983 . Poor reversibility is also maintained in solubilised receptor preparations (Nicholson et al. 1988a) . In contrast to this, the rat C1b receptor exhibits rapid and complete reversibility of sCT binding (Houssami et al. 1994a) .
Calcitonins, particularly 'fish-like' CTs such as sCT, are widely used therapeutically in the treatment of bone disorders, including Paget's disease, osteoporosis and hypercalcaemia of malignancy (Azria et al. 1995) . One of the major problems in the clinical use of CT is 'escape' from its action on bone, which is thought to be due, at least in part, to potent down-regulation of CTRs (Wada et al. 1996a, b) . In this regard, the poor reversibility of sCT is likely to contribute to the severity of the escape response and yet little work has occurred addressing the kinetics of CT interaction with its receptor.
Essentially, all studies on the kinetic behaviour of ligands at CTRs have employed sCT. Thus, it is unclear whether the poor reversibility of sCT is a property of the peptide per se or arises from the mechanics of ligand interaction with particular conformational states of the receptor (or a combination of these parameters). In the current study, both rat and human receptors have been studied as these form the principal targets for experimental and therapeutic use respectively. In addition, while interaction of receptors with ligands across these two species is similar, it is not identical (Houssami et al. 1995) .
This paper addresses the nature of the reversibility/ irreversibility of CT binding to cloned rat and human CTRs. Poor reversibility was a property of agonist peptides and the rate of dissociation was greater for peptides with lower potential to form an amphipathic -helix. The poor dissociation of sCT, however, was essentially independent of G protein coupling.
Materials and Methods

Hormones and chemicals
Synthetic sCT, hCT and sCT(8-32) were from Bachem (Torrance, CA, USA.). AC512 and 125 I-AC512 were a gift from Glaxo Wellcome (Research Triangle Park, NC, USA) and Amylin Pharmaceuticals (San Diego, CA, USA). The analogues, sCTA1, sCTA2, sCTA3, sCTA4 and sCTA5 were a gift from Dr Richard Epand (Department of Biochemistry, McMaster University, Ontario, Canada). The chimeric sCT/hCT analogues, H16 SCT (ACT15), H21 SCT (ACT19), H13 SCT (ACT20) and S16 HCT (ACT27), were a gift from Dr Masataka Ohba (Asahi Glass Co. Ltd, Kanagawa, Japan) and Dr Eigoro Murayama (Chugai Pharmaceutical Co., Shizuoka, Japan). The N-terminally truncated analogues, SDZ-212-769, SDZ-216-710 (ASC710), , were a gift from Dr Rainer Gamse (Sandoz Pharma Ltd, Basel, Switzerland). Structures of the analogues are listed in Table 1 . Bovine serum albumin (BSA) was obtained from Commonwealth Serum Laboratories (Parkville, Australia). Bacitracin, isobutylmethylxanthine (IBMX) and phenylmethylsulphonylfluoride (PMSF) were purchased from Sigma Chemical Co. (St Louis, MO, USA). G418 (Geneticin) was obtained from Gibco (Grand Island, NY, USA). Na 125 I and 125 I-hCT were from Amersham (Sydney, Australia). All other chemicals were reagent grade or better.
Iodination of sCT, sCT analogues and sCT/hCT chimeras
Synthetic sCT, sCT analogues and sCT/hCT chimeric peptides were iodinated as previously described (Nicholson et al. 1986) , with 125 I using 5 µg chloramine T for 10 s as oxidant, purification with the silica resin QUSO G32 (North America Silica Co., NJ, USA.), and elution with 20% acetone-1% acetic acid. The iodinated sCT/ hCT chimeras were further purified by reverse phase-HPLC to remove the oxidised form of the radioligand, using a Brownlee C8 column (30 4·6 mm) and gradient elution of 0-60% (v/v) acetonitrile/0·1% (v/v) trifluoroacetic acid. Specific activity of 125 I-sCT was 700 Ci/mmol. Specific activities for HPLC purified peptides Dulbecco's modified Eagle's medium (DMEM) containing 5% heat-inactivated fetal bovine serum and 200 µg/ml G418 in a humidified atmosphere of 5% CO 2 . The BHK cell lines, stably transfected with either the hCT receptor lacking (hCTR I1 ; 30 000 receptors/cell) or containing (hCTR I1+ ; 20 000 receptors/cell) the 16 amino acid insert in the first intracellular domain were a gift from Dr Emma Moore (Zymogenetics, Inc., Seattle, WA, USA) (Kuestner et al. 1994 . The HEK-293 cell line stably expressing the rat C1a receptor isoform (60 000 receptors/cell) was prepared as previously described (Houssami et al. 1994a) . Mock transfected or untransfected cells did not exhibit specific 125 I-sCT binding and lacked cAMP responses to CT peptides (Houssami et al. 1994a , Kuestner et al. 1994 .
Receptor binding assay
For competition binding studies, the growth medium of cells in 24-well plates (Costar, Cambridge, MA, USA) was replaced with binding buffer (DMEM containing 0·1% (w/v) BSA and 0·1% (w/v) bacitracin). 125 I-sCT (80 pM) was added to the wells in the absence (total binding) and presence of increasing concentrations of unlabelled ligands. Nonspecific binding was defined as binding in the presence of 10 -6 M unlabelled sCT. After incubation for 1 h at 37 C in 5% CO 2 , cells were washed with phosphate-buffered saline (PBS; 140 mM NaCl, 2 mM KCl, 1 mM KH 2 PO 4 , 8 mM Na 2 HPO 4 ), at 4 C, to remove unbound radioactivity and then solubilised with 0·5 ml 0·5 M NaOH. Samples were counted in a Packard -counter (70% efficiency) to determine bound radioactivity. Concentrations of peptides yielding 50% inhibition of 125 I-sCT binding (IC 50 ) were determined using a 4 parameter logistic fit in Sigmaplot (Jandel Scientific, San Rafael, CA, USA). In one series of experiments, competition binding with unlabelled peptides was initiated at increasing time intervals after the addition of 125 I-sCT.
In these experiments incubation with 125 I-sCT was carried out for 90 min and competing peptides added at t=0, t=15, t=30, t=45 and t=60 min after the addition of 125 I-sCT. The results shown are representative of at least two separate experiments performed with triplicate repeats. Between experiment variation was less than 10%.
cAMP assay
Cells were grown to confluence in 24-well plates and pre-incubated for 20 min at 37 C in 5% CO 2 in DMEM containing 0·1% BSA and 1 mM IBMX. Cells were subsequently incubated for 20 min at 37 C in the absence (basal) or presence of increasing ligand concentrations. The Table 1 Structure of amino-terminal truncated sCT analogues, sCT/hCT chimeric peptides and sCT analogues with differing capacities to form -helical secondary structure. Comparison of the secondary structure potential of the sCT analogs is expressed as helical secondary structure in the presence of dimyristoylphosphatidylglycerol (DPMG). The mean residue ellipticity ( ) at 222 nm becomes more negative as a result of increased secondary structure, particularly helical structure. The source reference for the circular dichroism data is indicated. The amino acids corresponding to the SCT sequence are depicted in bold type face cells were washed with 0·5 ml PBS prior to extraction of cAMP with 0·5 ml absolute ethanol. Levels of cAMP were then assayed using a specific radioimmunoassay, as described previously (Houssami et al. 1994b ). The concentration of peptides yielding 50% of the maximal response (EC 50 ) was determined using Sigmaplot. The results shown are representative of at least two separate experiments performed with triplicate repeats. Between experiment variation was less than 15%.
Binding kinetics: association and dissociation of 125 I-ligands
Cells Cells in 24-well plates were incubated in binding buffer containing 125 I-ligand (50 000 c.p.m.) in the absence (total binding) or presence of 10 6 M sCT (nonspecific binding) at 37 C in 5% CO 2 . To determine association rates, 125 I-ligand was added to wells and, at the times indicated thereafter, cells were washed with PBS and then solubilised with 0·5 ml 0·5 M NaOH to determine cell-bound radioactivity. To determine dissociation rates, cells were incubated for 1 h at 37 C with 125 I-ligand and then washed with PBS prior to the addition of fresh binding buffer containing 10 6 M unlabelled sCT. At times thereafter, dissociated radioactivity was removed by washing with PBS. Cell-associated 125 I-ligand was determined by solubilising the cells with 0·5 ml 0·5 M NaOH before counting in the -counter. The results shown are representative of at least two separate experiments performed with triplicate repeats. The observed association rate constant (K obs ) and half time for dissociation (t 1/2 ) values for the individual peptides were calculated using the program KINETIC (Version 4; Biosoft, Cambridge, UK).
Membranes
Cell membranes from HEK-293 cells stably expressing the C1a receptor were prepared as previously described (Houssami et al. 1994b ). Membranes were thawed and centrifuged at 48 000 g for 20 min at 4 C and rehomogenised in 50 mM Tris-HCl buffer, pH 7·3, containing 1 mM EDTA, 1 mM PMSF, 0·1% bacitracin and 0·1% BSA. Aliquots of membranes (0·014 mg protein) were incubated with 125 I-sCT in binding buffer in the presence or absence of 20 µM GTP S for 30 min at 37 C. Reactions were terminated by centrifugation at 48 000 g for 4 min at 4 C and the supernatants removed. The pellets were overlaid with ice-cold 0·5 ml PBS and centrifuged again for 4 min and the PBS aspirated. Fresh binding buffer with or without GTP S containing 10 7 M unlabelled sCT was then added and placed at 37 C. At times thereafter, the samples were centrifuged and washed as above. The pellets were recovered by cutting off the end of the centrifuge tube and were counted in a Packard -counter. Experiments were performed at least twice with triplicate repeats.
Results
In initial experiments, we examined the interaction of hCT with hCTR I1 receptors and the rat homologue (C1a). Human CT was essentially equipotent with sCT in stimulating cAMP production at the hCTR I1 receptor and was 10-fold less potent than sCT at the rat C1a receptor ( Table 2) . Analysis of the dissociation rate of 125 I-hCT indicated that hCT binding was rapidly and fully reversible at both receptors, with half times for dissociation (t 1/2 s) of 21 and 36 min for rat and human CTRs respectively (Table 2 ). In contrast, 125 I-sCT exhibited a t 1/2 of >240 min for both receptors (Table 2) .
Despite essentially equivalent potency in stimulating adenylate cyclase, hCT was 100-fold less potent than sCT in competing for 125 I-sCT binding at the hCTR I1 receptor ( Table 2 ). We have speculated that the potency of peptides in competition for binding of 125 I-sCT principally reflects affinity for the inactive-state receptor (Houssami et al. 1995) . Thus, the rapid dissociation of hCT may reflect a decreased affinity of hCT for the inactive state of the receptor. However, the antagonist peptides AC512 and sCT(8-32) competed for 125 I-sCT binding with equal or 10-fold lower affinity, respectively, than sCT (Table 2) . Despite this, both antagonist peptides exhibited rapid and complete dissociation from the receptors (Table 2) . This Houssami et al. (1995) .
suggests that the affinity of ligands for the inactive state of the receptor is not critical in the poor dissociation of CT from its receptors.
To examine the role of G protein in the kinetics of sCT binding, the dissociation of 125 I-sCT binding was examined in membrane preparations of cells stably expressing the rat C1a receptor. As seen in whole cells, 125 I-sCT showed minimal dissociation, with 60% of binding still present after 4 h (Fig. 1) . Disruption of G protein coupling by the addition of the non-hydrolysable GTP analogue, GTP S (20 µM) had little effect on the rate of ligandreceptor dissociation (Fig. 1) .
The transition of 125 I-sCT binding to irreversibility was examined in competition binding experiments where the unlabelled competing peptide was added at increasing time periods after the addition of 125 I-sCT. Experiments were performed on cells expressing the rat C1a and hCTR I1 receptors, as well as the G protein coupling deficient hCTR I1+ isoform. The results indicated that the binding of sCT becomes progressively irreversible over time, with 70% of binding irreversible by 60 min. Similar rates of transition to irreversibility were observed for all 3 receptors (Fig. 2) . Competition binding curves were established using sCT, as well as the reversible antagonist peptide, sCT(8-32), and the reversible agonist peptide, hCT. Although >50% of binding was irreversible by 45 min, the competition binding curves for each of the peptides remained parallel over this time period (Fig. 3) .
To determine which regions/residues of sCT contribute to its irreversible binding at rat and human CTRs, we subsequently investigated the binding kinetics of a series of sCT analogues with structural modifications, which included amino terminal truncations, chimeric sCT-hCT peptides and sCT analogues with differing potentials to form an amphipathic -helix.
Amino-terminal truncations of sCT
Analysis of binding kinetics for full length and minimally modified truncated sCT peptides revealed a more rapid rate of dissociation with decreasing peptide length (Table  3) . This was most striking for the rat C1a receptor but was also evident for the human receptors (Table 3) . Association rate constants were proportional to dissociation rates, presumably reflecting the greater time to reach equilibrium for slowly dissociating peptides.
Analogues intermediate in length between sCT(1-32) and sCT(8-32) may act as either agonists or antagonists ( Table 3 ). Deletion of 1 or 2 residues did not significantly alter either binding affinity or efficacy of peptides in inducing accumulation of cAMP (Table 3 ). However, deletion of 6 or 7 amino acids resulted in a complete loss of agonist efficacy (Table 3) , with only 3-to 10-fold reduction in binding affinity.
Modified analogues
While remaining a full agonist at all 3 receptors, the modified analogue of sCT(3-32) (SDZ-219-378) exhibited a 10-fold increase in IC 50 and EC 50 values, and a corresponding decrease in t 1/2 values (Table 3 ). The equivalent modifications to the antagonist peptide sCT(8-32) (SDZ-219-379) did not appear to significantly alter its IC 50 , which was similar to that of sCT(8-32), and both peptides exhibited fully reversible binding (Table 3 ). The modified sCT(5-32) analogue (SDZ-216-710) maintained an equivalent IC 50 to the shorter unmodified or minimally modified peptides and exhibited poorly reversible binding, particularly for the hCTRs, with t 1/2 s of 165 and 204 min for hCTR I1 and hCTR I1+ respectively (Table 3) . Although no adenylate cyclase response is seen with SDZ-216-710 at the hCTR I1+ , it is a weak agonist at the rat C1a receptor and a full agonist at the hCTR I1 (Table 3) , indicating that it interacts with active state receptor.
Salmon CT-human CT peptide chimeras
As described above, hCT is unlike sCT in that it is fully dissociable from the receptors. Hence, we examined the kinetic behaviour of peptide chimeras, generated by substitution of sCT residues with corresponding hCT residues.
In competition binding and cAMP accumulation studies, sCT peptides which have been substituted at the N-terminus by 13-21 residues of hCT (H13SCT, H16SCT, H21SCT; Table 1 ) exhibited similar IC 50 and EC 50 values to sCT (Table 4) . A reverse chimera sCT (1-16)-hCT(17-32) (S16HCT) was 2-to 10-fold less potent in competition for 125 I-sCT binding or cAMP production (Table 4) . Surprisingly, the more potent analogues (H13SCT, H16SCT and H21SCT) all exhibited rapid and complete dissociation from the receptors, with t 1/2 s similar to that for hCT (Table 4) . Conversely, 125 I-S16HCT binding was essentially irreversible at the hCTRs and displayed slow reversibility at the rat C1a receptor, with a t 1/2 of 58 min (Table 4 ). Thus, residues in the N-terminal half of sCT are important in the slow rates of dissociation of the peptide.
Salmon CT analogues with differing capacity to form -helical secondary structure
We next examined the dissociation kinetics of sCT analogues with differing ability to generate helical secondary structure to determine the contribution of this feature to the irreversible binding of sCT. The analogues and their degree of inducible secondary structure in the presence of lipid are listed in Table 1 . Houssami et al. (1995) . Table 5 IC With the exception of sCTA4, there was a good correlation between the ability of analogues to form amphipathic -helical secondary structure and the rate of dissociation from the receptors with sCTA1> = sCTA2>sCTA5> =sCT ] sCTA3 ( Table 5 ). The analogues displayed similar rates of dissociation at the hCTRs, although sCTA1 and sCTA2 dissociated more slowly from the insert-positive receptor isoform (Table 5 ). As seen with other analogues, a similar overall pattern of dissociation rates was observed at all of the receptors; however, dissociation from the rat C1a receptor was generally more rapid than from the hCTRs (Table 5) , with analogues exhibiting poorly reversible binding at the hCTRs having reduced rates of dissociation at the C1a receptor. This is particularly striking for sCTA5 which has t 1/2 s of >240 min at the hCTRs and 37 min at the rat C1a receptor. Although sCTA4 maintains a capacity to form an amphipathic -helix greater than sCTA5, sCTA4 binding was rapidly reversible (Table 5 ). However, this peptide exhibits lower affinity and efficacy than sCT at the receptors, being essentially without agonist activity at the rat C1a and hCTR I1+ receptors (Table 5 ). This suggests that it only weakly interacts with the active state(s) of the receptors.
Association rates
The rate of association of the radiolabelled analogues with the receptors was measured. A positive correlation was seen between the rate of dissociation and the observed association rate constant for the radiolabelled analogues at the receptors, reflecting the increased time required to reach equilibrium for slowly dissociating peptides (Table 6 ).
Discussion
In this study, we have investigated the kinetics of CT binding to its cognate receptors; in particular we have probed the underlying basis for the poor reversibility of sCT-like peptides from CTRs. The binding of sCT to both human and rat CTRs could be separated into a reversible component and an irreversible component. Competition analysis of the reversible component demonstrated parallel binding curves for competing peptides with divergent kinetic behaviour. This is indicative that the reversible component of binding is in pseudoequilibrium and that binding is predominantly to a single population of sites or receptor states, although it is possible that the data reflect a constant ratio of mixed receptor conformations. Under the conditions of assay (in whole cells), guanine nucleotides are in excess. The relative affinities of ligands are therefore likely primarily to reflect binding to the inactive state (G protein uncoupled) of the receptor (Houssami et al. 1995) . The appearance of the irreversible component was essentially linear with time for each of the receptors studied, but was relatively slow in appearance with 50% of binding reversible after 45 min exposure to ligand.
Only peptides capable of interacting with the active state of the receptor demonstrated poor reversibility; peptides with antagonistic properties (such as AC512 or sCT(8-32)) exhibited rapid and complete reversibility despite having apparent binding affinities similar to sCT. The requirement for active state receptor (R*) is consistent with the observed persistent activation of adenylate cyclase seen with sCT in a number of cell lines expressing endogenous CTRs (Michelangeli et al. 1983) . In these cells, prolonged activation of the receptor appears to be dependent upon continued receptor occupancy, as acid-washing (which removes cell-surface bound ligand) abrogated the persistent activation (Michelangeli et al. 1983) . This association of tightly-bound ligand with signal transduction supports the involvement of the active state of the receptor in irreversible binding. However, the irreversible binding was not due to internalisation of receptors as neither the rat C1a nor the hCTR I1+ receptors undergo significant internalisation during the period of study (Houssami et al. 1994a . This is also consistent with the poor reversibility of binding in membrane preparations (current study) and solubilised receptor preparations (Nicholson et al. 1988a) where receptor internalisation cannot occur.
The poor reversibility of sCT was essentially independent of G protein interaction since poor reversibility was maintained in both whole cells and in membrane preparations in the presence of GTP S. Furthermore, poor dissociability was observed in the hCTR I1+ -expressing cells, which exhibit modified G protein coupling efficiency . These results are concordant with earlier observations, which demonstrated that 'irreversibility' of 125 I-sCT binding was independent of the system of assay, occurring in whole cells (Findlay et al. 1981 , Chao & Forte 1983 , membranes (Fischer et al. 1981 , Nicholson et al. 1988b ) and solubilised receptor (Nicholson et al. 1988a) preparations. Although there have been few detailed studies on ligand-receptor binding kinetics for other members of the family B G protein coupled receptors, poor reversibility of agonist ligands has been observed with glucagon, PACAP and PTH/PTHrP receptors (Mitchell et al. 1990 , Post et al. 1993 , McArdle et al. 1994 . For the glucagon receptors, poor reversibility was at least partially dependent on the presence of associating G proteins (Post et al. 1993) and was attributed to stabilisation of the R*L (L=ligand) complex by the G protein.
Peptide structure and activity
There was a good correlation between dissociation rates and the ability of peptides to form amphipathic -helical secondary structure. With the exception of sCTA4, the greater the inducible -helical secondary structure, as measured in the presence of lipid, the lower the rate of dissociation. No strong correlation was observed between IC 50 or EC 50 values and dissociation kinetics, although the overall affinity of peptides for different receptor conformations is likely to be important. For example, binding of sCTA4 (G 2,3,4,5,6 analogue of sCT) was rapidly reversible from all of the receptors, despite a relatively high potential to form -helical secondary structure. This analogue has a markedly reduced affinity and efficacy for the receptors, consistent with a role for specific interactions between residues within the loop of the peptide and the receptor in agonist binding.
Salmon CT peptides lacking the N-terminal 7 or 8 amino acids present as antagonists, while peptides intermediate in length between 1-32 and 9-32 exhibit a progression from full agonist to partial agonist to antagonist (Feyen et al. 1992) . A similar pattern of response was seen in the current study where analogues with 1 or 2 N-terminal residues removed were equipotent with full length sCT, while removal of 4 or 6 residues led to a decrease or loss, respectively, of agonist efficacy. Analysis of binding kinetics for N-terminally truncated sCT peptides revealed more rapid dissociation with decreasing peptide length, although this was more pronounced for the rat C1a receptor than for the hCTRs. It has been suggested that interaction occurs between the amino terminus of sCT and other parts of the ligand (Epand et al. 1986 ). Indeed, nuclear magnetic resonance structural analysis of sCT indicates that C-terminal residues of the loop region interact with proximal residues of the predicted amphipathic -helix (L 9 , K 11 ). Furthermore, serine, threonine and asparagine residues, which are enriched in the loop region, have been shown to act as stabilisers of the N-terminus of an -helix (Meadows et al. 1991) . Thus, loop residues may be important for the stabilisation of the amphipathic -helix. Similarly, maintenance of the disulphide bridge may also stabilise secondary structure. This is supported by the loss of helical secondary structure between sCTA2 and sCTA5, where the primary difference in the peptides is cysteine to alanine substitutions at positions 1 and 7 in sCTA2 (Table 1 ). If such interactions occur, they may partially underlie the increased dissociation rates seen with N-terminally truncated analogues, particularly at the C1a receptor. An exception to this was the modified analogue of sCT(5-32) (SDZ-216-710), which exhibited slower or similar dissociation rates to longer analogues. It is possible that the isocaproyl modification at the N-terminus provides some stabilisation of the -helix. Similarly, it is possible that the Bolton-Hunter group at the N-terminus of the sCT(9-32) analogue, AC512, may serve to stabilise its secondary structure and thus explain its improved binding affinity at the CTRs compared with sCT(8-32). We have shown previously that the potential to form an -helix contributes to the binding affinity at CTRs (Houssami et al. 1995) . However, neither AC512 nor sCT(8-32) interact with the active state of the receptors and are both fully reversible.
We previously reported that C-terminal residues (16-32) of sCT are important for high affinity interaction with rat or human CTRs (Houssami et al. 1995 ). In the current study, we found that the H21SCT analogue was equipotent with sCT, indicating that determinate residues for high affinity interaction with the receptors reside in the 22-32 region of sCT. Consistent with this, substitution of sCT with hCT at the N-terminus generated peptide chimeras (H13SCT, H16SCT and H21SCT) with binding affinities and efficacies similar to sCT; however, the dissociation rates were similar to hCT. In contrast, substitution of the C-terminal 16 amino acids generated a chimera (S16HCT) with similar dissociation rates to sCT at the hCTRs, and only slow reversibility at the rat C1a receptor, despite reduced efficacy at the receptors. S16HCT contains the first 16 amino acids of sCT, suggesting that this region of sCT is involved in the transition to irreversibility. With the exception of a Ser-Gly substitution at position 2, amino acids 1-7 of sCT and hCT are identical. Furthermore, this residue may be deleted (SCTA3) without affecting the behaviour of the peptide, indicating that the 8-16 region is critical in the poor reversibility of sCT. The 8-16 region of sCT is capable of generating an amphipathic -helix (Siligardi et al. 1994) and circular dichroism analysis indicates that S16HCT adopted a similar degree of -helical secondary structure to sCT in aqueous conditions. Conversely,
